WINNIPEG, Manitoba, November 14, 2011 - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the “Company”) today reported its results for the third quarter 2011.  All figures are reported in US dollars.

2011 Highlights:

• Three new system sales contribute to order backlog increasing to $102 million at September 30, 2011
• Global expansion continues with first VISIUS Surgical Theatre sale in Japan
• First published papers on VISIUS Surgical Theatres report positive results
• Surgical robot development continues with first demonstration at CNS in Washington, D.C.
• VISIUS Surgical Theatre^TM launched as new global product branding

During the third quarter of 2011, IMRIS received orders for three VISIUS Surgical Theatres reflecting an improving trend from the first two quarters of the year.  Revenues in the third quarter were $7.2 million and $37.1 million in the first nine months of 2011 compared with $16.8 million and $45.4 million during the third quarter and first nine months of 2010 respectively.  The lower 2011 revenues reflect changes in customer schedules that resulted in certain installation activities being advanced to future quarters. Planned increases in 2011 operating expenses for the Company’s focused product development efforts together with increases to support future growth in the business contributed to net losses of $8.5 million in the third quarter and $16.0 million in the first nine months of 2011 compared with net income of $0.7 million in the third quarter of 2010 and a net loss of $2.7 million in the nine months ended September 30, 2010. 

 “The current macroeconomic environment and associated uncertainty is having an impact on capital spending by hospitals and we are seeing that translate into longer sales cycles and longer installation times.” said David Graves, IMRIS CEO. 

Read More...